Similarly, in a rat model of liver fibrosis, co‐treatment with bone marrow‐derived MSCs and Imatinib, another tyrosine kinase inhibitor, showed enhanced reduction of fibrotic markers, such as α‐SMA and collagen, with better histopathological improvement than either therapy alone [143]. This evidence concerns the gene ACTA1 and Hepatic fibrosis.